Leveljump Appoints New Director of Sales and Creates Advisory Board to Accelerate Company Growth

LevelJump Healthcare Corp. (TSXV: JUMP) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce the appointment of a new sales and marketing director as well as the formation of an Advisory Board that will provide guidance to the Company on matters related to planning and executing the Company's M&A strategy.

As part of the Company's plans to expand its teleradiology services and to build a national brand as a leading supplier of remote emergency room radiology solutions, Leveljump's operating subsidiary Canadian Teleradiology Services, Inc. ("CTS") has appointed a Director of Sales and Marketing. The role of the new sales and marketing director will be to focus on growing the client base of CTS and securing new multi-year contracts for CTS. The Director of Sales and Marketing will also oversee all efforts to grow emergency room support and to provide services to private diagnostic imaging centers.

The Advisory Board will assist the Company in identifying new potential M&A targets as well as assist with the due diligence process, deal negotiations and structuring, and concurrent financing.

Members of the newly established Advisory Board include:

Mr. Lowell Kamin, a veteran financial services executive with over 25 years of capital markets experience who has held leadership roles in prominent North American investment banks. Having worked in the institutional equity sales division at Scotia Capital Inc. and the Bank of America Merrill Lynch, now known as BofA Securities, Inc., Lowell has completed various equity and debt financings for a broad range of public and private Canadian & U.S. companies. Prior to that, Lowell was an Investment Advisor at Scotia McLeod.; and

Mr. Gary Prihar, CPA, CA, an accomplished consultant who will bring comprehensive and key industry knowledge to spearhead advanced training in outreach, telemedicine, and expansive growth strategies for Leveljump. Being a holder of the CPA and CA designation, Mr. Prihar's experience will empower the management team with an intimate understanding of the dynamics that create a platform for highly successful interactions between provider and recipient.

"The formation of the Advisory Board is pivotal to the growth strategy of the Company and we are pleased to add a team of talented individuals to our advisory board," said Mitchell Geisler, Chief Executive Officer of Leveljump Healthcare. "In addition, we are also pleased to welcome a new sales and marketing director who will play an integral part in our marketing campaign to rapidly expand the sales growth of CTS."

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LevelJump Healthcare Corp.

Mitchell Geisler
Chief Executive Officer
info@leveljumphealthcare.com
(877) 722-6965

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71476

News Provided by Newsfile via QuoteMedia

Leveljump Healthcare TSXV:JUMP Emerging Tech Investing

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

The Company is also pleased to announce the appointment of Mr. Wayne Myles, KC, FIIC, to its board of directors. An active investor and entrepreneur, Mr. Myles has served as lead counsel and strategic business advisor on more than 100 domestic and international acquisitions and sales, financings, government and regulatory affairs and licensing mandates. He has significant and diverse experience as a director of public and private companies. He also has been recognized with numerous professional achievements, distinctions and awards, including being named as one of "Canada's Top 25 Most Influential Lawyers' by Canadian Lawyer Magazine."